orphan orph
They do not need off label use. The company has 12 million shares outstanding.
Provigil is first line therapy for narcolepsy for excessive daytime sleepiness. It is a stimulant that keeps a person awake during the day. that doesn't mean a person doesn't FEEL LIKE SHIT.
Xyrem would be used at night to help the person sleep better. You are going to the route of the disease so the person stays awake the next day because they don't feel as tired. They could always take provigil with xyrem, the study showed they worked synergistically.
With narcolepsy being as the press release says there are 50 to 75000 people with narcolepsy seeking treatment for the disease. With xyrem treatment costing 10,000 a year that makes the market potential 500 to 750 million a year.
The drug is already approved, if they get a 20 percent penetration rate they will make a lot of money.
The ramp has taken a while but the more people that use it and are helped by it makes the docs more comfortable to perscribe it.
The company has a study that was don by a doctor schwartz in a fibro study. The data looked pretty good.
A lot of people with depression are not helped by ssri's. Some of them have sleep disorders that cause the depression. this is another huge market but the company would not at this time go after the market. Could you imagine what would happen if one of these people committed suicide while taking the drug.
this is a cheap stock that will not neccessarilly make the front pages or double in two weeks but over time it should go up much like uthr has. A slow ramp with additional news that gets attention with eventual increased sales.
Market Data 
Markets 
AI
